BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24479372)

  • 1. The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors.
    Seliger B
    J Immunotoxicol; 2014 Oct; 11(4):308-10. PubMed ID: 24479372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of classical and non-classical HLA class I antigens in human tumors.
    Bukur J; Jasinski S; Seliger B
    Semin Cancer Biol; 2012 Aug; 22(4):350-8. PubMed ID: 22465194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells.
    Romero I; Martinez M; Garrido C; Collado A; Algarra I; Garrido F; Garcia-Lora AM
    J Pathol; 2012 Jul; 227(3):367-79. PubMed ID: 22451343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors.
    Seliger B
    Cancer Immunol Immunother; 2008 Nov; 57(11):1719-26. PubMed ID: 18408926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC class I antigens and immune surveillance in transformed cells.
    Aptsiauri N; Cabrera T; Garcia-Lora A; Lopez-Nevot MA; Ruiz-Cabello F; Garrido F
    Int Rev Cytol; 2007; 256():139-89. PubMed ID: 17241907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel insights into the molecular mechanisms of HLA class I abnormalities.
    Seliger B
    Cancer Immunol Immunother; 2012 Feb; 61(2):249-254. PubMed ID: 22120755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
    Dhatchinamoorthy K; Colbert JD; Rock KL
    Front Immunol; 2021; 12():636568. PubMed ID: 33767702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
    Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
    Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours.
    Manning J; Indrova M; Lubyova B; Pribylova H; Bieblova J; Hejnar J; Simova J; Jandlova T; Bubenik J; Reinis M
    Immunology; 2008 Feb; 123(2):218-27. PubMed ID: 17725605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin.
    Seliger B; Wollscheid U; Momburg F; Blankenstein T; Huber C
    Tissue Antigens; 2000 Oct; 56(4):327-36. PubMed ID: 11098932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation.
    Zheng P; Guo Y; Niu Q; Levy DE; Dyck JA; Lu S; Sheiman LA; Liu Y
    Nature; 1998 Nov; 396(6709):373-6. PubMed ID: 9845074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells.
    Garrido C; Paco L; Romero I; Berruguilla E; Stefansky J; Collado A; Algarra I; Garrido F; Garcia-Lora AM
    Carcinogenesis; 2012 Mar; 33(3):687-93. PubMed ID: 22219178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.
    Seliger B; Ferrone S
    Methods Mol Biol; 2020; 2055():325-350. PubMed ID: 31502159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MHC class I antigens, immune surveillance, and tumor immune escape.
    Garcia-Lora A; Algarra I; Garrido F
    J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MHC class I down-regulation: tumour escape from immune surveillance? (review).
    Bubeník J
    Int J Oncol; 2004 Aug; 25(2):487-91. PubMed ID: 15254748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases.
    Guardiola J; Maffei A
    Crit Rev Immunol; 1993; 13(3-4):247-68. PubMed ID: 8110378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective HLA class I antigen processing machinery in cancer.
    Cai L; Michelakos T; Yamada T; Fan S; Wang X; Schwab JH; Ferrone CR; Ferrone S
    Cancer Immunol Immunother; 2018 Jun; 67(6):999-1009. PubMed ID: 29487978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards an extension of the two-variable model of carcinogenesis through oncogenes and tumour suppressor genes.
    Tourvas AD; Frangos CC
    Med Hypotheses; 2011 Dec; 77(6):956-8. PubMed ID: 21903334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
    Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
    Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.